



8TH ANNUAL
**ANIMAL HEALTH, NUTRITION
& TECHNOLOGY INNOVATION
EUROPE**

6-8 March • London, UK
@AHInnovation #AHTNI

INNOVATION SHOWCASE FINALISTS 2023

Animal Health, Nutrition and Technology Innovation Europe is the premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition. It connects those businesses with financial investors and strategic corporate partners.

ANIVIVE

Buddy

CANCAN
DIAGNOSTICS

dendro pharm

eQcell
One-Health Since 2010

NoBACZ Healthcare
Precision Bandaging

Xetirus™
Pharmaceuticals

Vedi

VICTORY GENOMICS
HORSEPOWER GENESIS

vidium
ANIMAL HEALTH eQCell subsidiary

PFMS
Poultry Farmers
Management System

Bioapp
BioApplications Inc.

EVAH
Evolution for Animal Health
Innovation for a better tomorrow

Farm Health Guardian™

Pastoral



TARGAN

WELLFISH DIAGNOSTICS

TVG
Vaccine Solutions for the 21st Century

VIROVET
Laboratory Solutions

We are proud to announce the **finalist companies** selected to present at the 2023 Innovation Showcase.

Headline
Partner:

zoetis

Platinum
Associate:

Elanco

IDEXX

MSD
Animal Health

Associate
Partners:

provaxs

GHENT UNIVERSITY

**McKinsey
& Company**

GHO CAPITAL

Pda
Paul Dick & Associates Ltd.

knoell
worldwide registration

argentā

SIEMENS Healthineers

vetoquinol
ACHIEVE MORE TOGETHER

Syngene
Putting Science to Work

A SPECIAL THANK YOU TO THE SELECTION COMMITTEE

The Selection Committee members were responsible for selecting the showcase companies at **Animal Health, Nutrition and Technology Innovation Europe 2023**. Each of our committee members has an extensive breadth of experience and knowledge across animal health and nutrition industries and will be available for meetings at the conference.



Charles Hoare
Managing Director, Head
of European Healthcare
Stifel



Julia Stephanus
Partner
Borealis Ventures



Phil Austin
Managing Partner
Anterra Capital



Paul Dick
President
Paul Dick & Associates



Cindy Cole
Partner
Digitalis Ventures



Jason Scott
Google and ANIM Fund



Tom Prins
Head of Dealflow
AquaSpark



Karolina Zapadka
Investor
Park Walk Advisors



Gentiane Gorlier
General Partner
The Yield Lab



Jamie Stein
Co-Founder
Devonian Capital



John McNicol
Founder and Director
Kelvin Capital



MAKE THE RIGHT CONNECTIONS

Our networking platform, Swapcard, allows you to preschedule meetings with these exciting start-ups!

Animal Health, Nutrition and Technology Innovation Europe is committed to bringing innovative and inspiring emerging companies together with partners looking to acquire and invest.

To ensure all our attendees make the most valuable connections possible at the Summit, the **Swapcard** platform allows you to create a bespoke meeting schedule, ensuring you connect with the industry stakeholders that are **most important** in building your business.

Swapcard gives you access to the entire attendee list and allows you to message AND invite people to connect during the formal meeting sessions that run throughout the day.

SCHEDULED MEETINGS

Who You Will Meet

- + Start-Ups & Early Stage Biotech Companies
- + Business Development Teams from International Pharmaceutical Companies
- + Leadership from Multinational Corporations
- + Mid to late-stage Health and Nutrition Companies
- + Global Distribution Leaders
- + Venture Capital and Private Equity Investors
- + Market Intelligence and Consultancy Providers
- + Universities and National Regulatory Bodies
- + Contract Research & Contract Manufacturing

Join the Finalists:
REGISTER TODAY



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Eun-Ju Sohn
CEO
BioApplications Inc.

BioApplications Inc. was founded in 2011 based on POSTECH's plant biotechnology and has made history with each challenge. BioApp developed plant-based vaccines that are safe for the environment and animals. The World's first plant-based classical swine fever vaccine, HERBAVAC™ CSF Green Marker vaccine, has been licensed and registered. In addition, we aim to play a key role in eradicating classical swine fever disease by contributing to being CSF-free in Korea and challenging the global market.

SERIES C

www.bioapp.co.kr



Michel Fortin,
President & Chief
Executive Officer
EVAH Corp.

EVAH Corp is a Canadian biotechnology company based in Quebec that is focused on developing animal health technologies. Our mission is to find better ways to feed the planet, address consumer needs for non-antibiotic protein, and increase the sustainability of food by fostering innovation.

EVAH is addressing a gap in the Animal Health Industry where large players partner with small biotech companies to create an animal health community. Research and innovation often stem from academic institutions, scientific community, and governments. EVAH will conduct the three phases of research and development and negotiate agreements with multinationals to monetize its technologies.

SERIES A

<https://www.evahcorp.ca>



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Tim Nelson
Founder and CIO
Farm Health Guardian

Launched into the market in 2021, **Farm Health Guardian** is a SaaS company, based in Guelph, Ontario. We have clients in USA, Canada, UK and EU. The Farm Health Guardian suite of products were created in order to reduce the financial and emotional devastation which occurs when animals get sick or die from preventable catastrophic and production limiting diseases.

Our focus is on the prevention of pathogen incursion and early detection, and we provide farmers, integrators, industry and governments with the information needed to proactively manage outbreaks and keep disease spread in check, in near real time.

SERIES A

www.farmhealthguardian.com



Josh Thomas
Co-Founder / CEO
Pastoral

Pastoral is a British digital regenerative livestock farming venture that provides lower-income farmers access to data and technology which supports decision-making that sequesters carbon and results in increased biodiversity, enriched soil, and healthier animals, which means less impact for more profit. Using Artificial Intelligence and a unique global IoT (internet of things) sensor suite, Pastoral is the world's only digital farming platform designed for the needs, price point, connectivity requirements, and technology readiness level of lower-income farmers in both wealthy and low-and-middle-income countries. Designed in partnership with the United Nations Development Program and the FAO, Pastoral is the first digital regenerative agriculture product with UN endorsement. Founded in England, Pastoral had its first overseas deployment in Uzbekistan, where the team spent nearly two years working with farmers in Ohangaron to fine-tune and launch the product.

SEED

www.pastoral.ai



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Henry Ngale Foretia
Founder & CEO
AIT Group (PFMS)

PFMS is an agtech start-up empowering small and medium-sized poultry farmers with the power of digital technologies. We developed a scientifically-proven, patent-pending early disease diagnosis image-based mobile app

The SaveTheChicken app helps poultry farmers instantly detect diseases at an early stage and connect with vets to diagnose and treat animal illness. When a farmer takes photos of the chicken feces at 30cm, our software will recognise the disease, and it will be confirmed by a certified Veterinarian before the diagnosis goes back to the farmer with over 92% accuracy plus friendly advice in real-time. Farmers have performed 993K diagnoses on the platform in over 1,000 locations worldwide, while over 200 million chickens were saved from infectious diseases. Our app makes diagnostics simple, affordable, and instant on any mobile phone for farmers to perform diagnostics by themselves, confirmed by a certified virologist before the results go back to the farmer with an opportunity to connect to a certified vet.

SEED

www.pfms.cm/products/5/stc-savethechicken-app



Daniel Burgin
CEO
T3 BioScience

T3 BioScience ("T3") is a privately held biotech firm, established in 2012, and is leveraging the solid foundation of nearly two decades of microbiological research by its founder and CSO, Dr. Ching-Hong Yang. T3 is launching its first product by the name of RejuAgro in the area of crop protection, with an initial focus on inhibiting the diseases of fire blight, citrus canker, and citrus greening. A preliminary EPA hearing was held in May 2018, and the product was classified under the microbial branch of the EPA. Submission to the U.S.' regulators is targeted for late 2023. The RejuAgro product series have shown significant inhibition efficacy in aquaculture with the Company's initial focus on the salmon and shrimp industries. RejuAgro was tested in vitro by a specialist CRO, confirming the product's high efficacy against globally important fish pathogens that cause streptococcosis, furunculosis, tenacibaculosis, acute hepatopancreatic necrosis disease, and gastrointestinal illness in humans. CRO testing on salmon and shrimp is planned for early 2023.


SERIES A

www.t3biosci.com



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Ramin Karimpour
Founder and CEO
TARGAN

TARGAN Inc. is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. TARGAN utilises its patented platform technologies to address clear needs for improved individual vaccine delivery, automated gender identification, health screening, and sorting within the animal production industry. TARGAN has developed multiple technology platforms utilising advanced high-speed imaging, artificial intelligence, conveyance, micro-dose vaccine/biologicals delivery apparatus to improve welfare and performance for various animal species. Utilising this platform, TARGAN is developing novel, automated solutions for the swine industry.

The device under development will incorporate conveyance, counting, identification, imaging, and automated vaccine delivery. The timing of administration will align with the movement of the piglets or pigs to new barns or locations within the barn. The system will use conveyance to ease the movement and restraint needed for vaccine or treatment delivery. As the pigs or piglets move down the conveyance system, they can be scanned for identification tags, the site of vaccination or treatment identified, and the substance administered.

www.targan.com



Vaccine Solutions for the 21st Century



Jeremy Salt
CEO
TVG

The Vaccine Group is a vaccine biotech start-up established in 2017 as spin out from the University of Plymouth, England. It is focused on a tuneable viral vector technology platform for gene delivery with immunological or biological function across domesticated and wildlife species.

TVG has established a pipeline of projects that address infectious diseases in animals that are either zoonotic, transferred from animals to humans, or have a serious commercial impact on livestock production, such as PRRS and African Swine Fever in pigs, and bovine tuberculosis in cattle.


SEED

www.thevaccinegroup.com/



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



Erwin Blomsma
CEO
ViroVetMV

ViroVet is an award-winning company dedicated to the development of disruptive technologies for the control of viral diseases in livestock, with innovative thermostable vaccines leading the pipeline.

The strategy of ViroVet is to provide its vaccines (in combination with antiviral drugs and existing biosecurity measures where relevant) in order to provide livestock producers, national governments and international organisations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.

SERIES C

www.virovet.com



Brian Quinn
CEO
WellFish Diagnostics

WellFish Diagnostics provides rapid, non-lethal fish health assessment for the aquaculture sector using blood-based clinical chemistry analysis. Using our unique database and AI models for data interpretation, we provide clinically interpreted results within 24h change our to of sample receipt, facilitating continuous health monitoring to support data-informed husbandry decisions, improving fish health & welfare management.

The primary market is a clinical chemistry-based diagnostic service to the aquaculture sector resulting in the generation of data used to improve fish health and increase productivity. A secondary market through product development of new, fish-specific diagnostic technologies (IP protectable) is currently being established. We are also developing PCR technology for the non-lethal assessment of pathogen identification and fish health in aquaculture reared salmon and trout.

SERIES A

www.wellfishdiagnostics.com



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS

ANIVIVE



Dylan Balsz
Founder & CEO
Anivive Lifescience

Anivive Lifescience is an animal pharmaceutical company leveraging the power of AI to revolutionise animal drug discovery and development. Our unique technology platform allows us to rapidly assess and de-risk drug candidates and significantly shorten the time to market. By using the power of AI, we are able to offer therapeutics for Fungal Vaccines, Infectious Disease Treatments and Oncology.

SERIES A & B

www.anivive.com

BUDDY



Ryan Johnson
COO
Buddycare

Built by vets, and loved by pets, **Buddycare** is here to protect your pet and pocket! Our team have over a century's worth of experience working within the veterinary profession, whether that be in clinics healing pets and saving lives, or running businesses both here in the UK, and overseas in the US

We have established three arms to Buddycare, with our telemedicine service, and subscription platform promoting preventative care at market leading prices. Whereas our new innovative take on pet insurance, which we're thrilled to announce will be launching in Q1 2023 as the flagship of the Buddy brand, will offer cover for when the unforeseen happens, and a pet is taken ill.

We have developed an innovative insurance model which does not charge clients any excess, will be the cheapest pet insurance on the market, covers end of life bills, and just as importantly, retains core clinic revenues too. Thus, making Buddycare insurance, good for the client, good for the pet, and good for vets in practice too.

SEED

www.buddycare.co.uk



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Maciej Parys
CEO
Can Can Diagnostics

CanCan Diagnostics is a spin out from University of Edinburgh, which aims at revolutionising canine cancer care in Europe through introduction of minimally invasive liquid biopsy for aid in diagnosis and monitoring. There are further plans in place to develop advanced methodology for specific early detection and diagnosis of most common canine cancers.

We have created a team with a diverse background and experience to both successfully develop the test as well as to then quickly commercialise it. We work with an UKAS/ISO accredited laboratory for our sequencing and are developing in-house analysis pipeline.

SEED

www.cancandiagnostics.com



Sam Dylan More
Chief Executive Officer
DendroPharm

DendroPharm GmbH develops innovative dendritic systems to improve drug transport. In addition to 4 PhD scientists, DendroPharm GmbH has a motivated and qualified international team that has many years of experience in the fields of dendritic polymer synthesis, cell biology, pharmaceuticals and drug regulatory affairs. Using our technology platform, we can develop specialty drugs for innovative medical and scientific applications.

SERIES A

www.dendropharm.de



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Thomas Koch
Founder, CEO & CSO
eQcell Inc

eQcell was incorporated to advance 15 years of research into mesenchymal stromal stem cells (MSCs) by Dr. Thomas Koch at the University of Guelph along a path of clinical development to establish a marketable veterinary product.

eQcell is developing a manufacturing platform of MSCs from multiple species and these cells can then be used in various ways for various clinical indications. MSC can be used to treat Equine, Canine and Human joint disease. Think of the MSC as the smartphone and the various usages as the apps on the smartphone, such as:

Equine joint disease:

MSC product to treat recurrent lameness from osteoarthritis due to non-infectious joint inflammation (synovitis) in horses

MSC product to treat septic arthritis in foals

Canine joint disease:

MSC product to treat Elbow Dysplasia

Human joint disease:

Tissue-engineered cartilage implant for cartilage resurfacing

www.eqcell.com



NoBACZ Healthcare
Precision Bandaging



Jonathan Powell
CEO
NoBACZ Healthcare Ltd.

NoBACZ Healthcare is a seed-stage spin out from Cambridge University with ambitions to disrupt the wound care market in animals and, downstream, in humans. The Company leverages cutting edge science to enable natural ingredients to produce a better 'bandage' that covers difficult-to-treat wounds in difficult-to-dress areas of the body. The result is a range of highly differentiated, sustainable, GRAS-compatible liquid barrier dressings that provide unsurpassed wound coverage while reducing the need for antibiotics.

Our first product is our ProTechX Bovine gel, a combination Hoof Healing and General Use product, aimed at helping farmers and vets tackle infectious lameness and debilitating udder wounds, will launch in 2023.

www.nobacz.com



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Robert Jordan
CEO
Vetirus Pharmaceuticals

Vetirus Pharmaceuticals was founded on the principal that nature holds the key to helping most disease states. Our focus is in the natural biologic space for both Human and Veterinary medicine.

Our current products treat Sarcopenia in Canines, Felines and Horses. Pipeline drugs include non-NSAID anti inflammatory and the treatment of Triaditis in Felines.

Vetirus Pharmaceuticals brings together a world class science, regulatory and business development team, expert in bringing products to market. They also bring selective search for under-served and target rich disease states that are both efficacious and profitable. Purity and Precision are the core of every decision we make.

vetirus.com

Vedi



Steve Joslyn
CEO & Co-Founder
Vedi

Vedi is a universal health record that locks to the animal's existing microchip - agnostic and additive. We connect vets, owners, animals and service providers seamlessly with verifiable, automated medical data, free of human error mistakes. Our animals have an implanted globally unique identifier that is always with them - we make sure that microchip is front and centre with every piece of data we handle or support.

Everything is based on the fact we have a verified animal, owner and vet data - so connecting our system to service providers brings efficiencies and verification that has never been seen before. The status quo is PIMS systems that are full of errors and duplications, all from human data entry. This removes the desire for 3rd party integrations with PIMS. We separate the EHR from the PIMS, allowing our data to improve the PIMS, but work for the animal and owner through the entire life journey. We link councils, and microchip registries with instant verifiable data feed from Vets and their PIMS. Zero errors, instant registrations and updates. Lost animals are quickly rehomed through our network of vets and stakeholders continuously scanning microchips.

SEED

www.vedi.io



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE INNOVATION SHOWCASE FINALISTS

COMPANION ANIMALS



Mustafa Khokha
Co-Founder and President
Victory Genomics

Victory Genomics applies the power of genome sequencing to improve the welfare of horses. The genome defines traits and so with genome sequencing we can identify DNA sequences that influence health, performance, and welfare. Whole genome sequencing creates a number of different products based on breed. Currently we have genome reports for Arabians, Thoroughbreds, and Anglo-Arabians. We plan to create products for Standardbreds and Quarter horses in the near future.

Victory Genomics is founded by Yale Professors with considerable expertise in human genomics who have translated that know-how to horses. Next generation sequencing has utterly transformed human health and Victory Genomics expects a similar transformation in the equine industry.

SEED, SERIES A

www.victorygenomics.com



David Haworth
President & Co- Founder
Vidium Animal Health

Vidium Animal Health is bringing the genomics revolution to veterinary medicine. We are the animal health subsidiary of City of Hope, one of the leading human cancer treatment centers in the world, and as such have exclusive access to some of the latest technologies being developed to extend and improve the lives of human cancer patients. Founded in 2019, we have provided a best-in-class genomic profiling test, SearchLight DNA(R), since mid-2020. We have seen consistently increasing adoption and will close out 2022 with more than \$690k in annual revenue. In 2022 we launched a specialty pathology service, recruiting three of the most respected veterinary oncopathologists in the world to our team. This not only provides an important revenue source and keeps us on the forefront of cancer diagnostics, but also creates significant halo effects for our other cancer diagnostic products.

In 2023, we will launch our third product: a cost-effective (\$150 to the veterinarian), blood-based cancer screening tool with significant advantages over other products in this space. The potential market size for this product is conservatively in the hundreds of millions of dollars.

SERIES A

www.vidiumah.com



ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE

VENUE & PRICING

etc. venues, 155 Bishopsgate, London EC2M 3YD

PASS TYPE*	EARLY BIRD PRICING
Showcase Applicant Only available to companies that have applied to present at the Innovation Showcase in 2022	£1,099 + VAT
Emerging Companies & Start Ups, Academics, Charities, Veterinary Practices, Angel and VC Investors For Start-Ups with under £4m in Annual Revenue Please note: Those offering consultancy or market intelligence services do not qualify for this rate	£1,199 + VAT
Delegate Health, Nutrition and Tech companies (under £100m in annual revenue)	£2,399 + VAT
Multinationals CROs, CMOs, Consultants, M&A Advisors, Private Equity, Incubators, Accelerators and Distributors and Companies over £100m in annual revenue	£3,499 + VAT

**Book before January 27th and save up to
£300 with early bird pricing**

SAVE 10% - Book a team of 3+

SAVE 15% - Book a team of 5+

**REGISTER
HERE**

Team discounts are only valid on industry rates and not in conjunction with any other offer or promotion. Payment Terms: Please note that all prices are plus VAT and a £49 processing fee will apply to any invoices requested. All Prices are in GBP. All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer. Please view our Cancellation Policy. QUESTIONS? Please email events@kisacoresearch.com.

